Get medical help right away if you develop any signs or symptoms of CRS at any time, including:
Most CRS events occurred during the first cycle of treatment for both IV infusion and subcutaneous injection versions of treatment. CRS occurred in 39% of people (86 of 218 people) who received an infusion, and in 30% of people (28 of 94 people) who received a subcutaneous injection.
CRS was generally managed with appropriate treatment in the clinical trial. CRS should be managed by your healthcare team
Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.
For people who received LUNSUMIO or LUNSUMIO VELO
The most common side effects of LUNSUMIO include: cytokine release syndrome, tiredness, rash, headache, fever, muscle pain, cough, itching, and numbness, tingling, or pain in the hands or feet (nerve damage).
The most common severe abnormal blood test results with LUNSUMIO include: decreased blood cell counts, decreased phosphate, increased glucose, and increased uric acid levels.
The most common side effects of LUNSUMIO VELO include: injection site reactions, tiredness, rash, CRS, COVID-19, muscle and joint pain, and diarrhea.
The most common severe abnormal blood test results with LUNSUMIO VELO include: decreased white blood cell counts and increased uric acid levels.
These are not all the possible side effects of LUNSUMIO or LUNSUMIO VELO. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Learn about the 2 ways treatment can be given and what to expect during treatment
A list of questions to help guide conversations with your healthcare provider
A type of immunotherapy used to find and destroy specific cells within the body (for example, the cells where follicular lymphoma starts). Antibody treatment can also harm healthy cells in the body.
A type of white blood cell that makes antibodies. B cells are part of the immune system and develop from stem cells in the bone marrow. FL is a type of B-cell lymphoma.
Bispecific antibodies are designed to target 2 different cells at the same time. For example, a bispecific antibody attaching to 2 different cells is thought to bring the cells together, such as an immune cell and a cancer cell.
The soft spongy material that fills the inside of bones. Bone marrow is the source of new blood cells, and platelets are made in the bone marrow.
Also called “complete response,” it is the disappearance of all signs of cancer in response to treatment. This does not mean the cancer has been cured.
A period of treatment followed by a period of rest (no treatment) that is repeated on a regular schedule.
Chemicals in your immune system that act like “messengers” and tell other cells in your immune system how to protect your body.
A serious side effect that happens when your immune system responds too strongly by rapidly releasing a large amount of substances known as cytokines. CRS may cause fever, fast or irregular heartbeat, low blood pressure, chills, or difficulty breathing.
A treatment that is designed to be administered for a prespecified number of cycles and with a targeted completion.
The most common type of indolent (slow-growing) non-Hodgkin lymphoma (NHL). With NHL, abnormal lymphocytes (white blood cells) build up in the lymph nodes, bone marrow, and spleen. FL develops when the body makes abnormal B lymphocytes, making it a type of B-cell lymphoma. FL can be a chronic disease.
Medicine delivered through a needle in your vein over a period of time.
A small bean-shaped organ that stores white blood cells.
A type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system. Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma.
A partial or complete remission.
Also called “partial response,” a measurable decrease of cancer in the body.
A type of clinical trial that studies an investigational treatment to test how well it works and monitors for potential side effects.
A term used to describe disease that has not responded to treatment.
A term used to describe disease that has returned after responding to previous treatment.
The reduction in (partial) or disappearance of (complete) signs and symptoms of cancer in response to treatment.
An organ that is part of the lymphatic system. The spleen makes lymphocytes (white blood cells), filters blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach.
A smaller dose of LUNSUMIO or LUNSUMIO VELO that you receive on Day 1 and Day 8 of your first cycle of treatment.
Medicine delivered under your skin, usually in your thigh or lower stomach area.
A type of white blood cell. T cells are part of the immune system, helping to protect the body from infection and may also help fight cancer. A subset, cytotoxic T cells, bind to and kill infected cells and cancer cells.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.